StockIQ.techRevolution Medicines, Inc. (RVMD) Stock Analysis
Free AI-powered analysis and research for Revolution Medicines, Inc. stock
Sector: Healthcare
RVMD snapshot
Data as of 9 Oct 2026 close. Updated daily.
Revolution Medicines, Inc. scores 13/100 on StockIQ's model, which reads as strongly negative signals overall. The price is above its 200-day average and at 80% of its 52-week range, up 293.4% over the past year. Latest reported figures show a profit margin of 0.0% and return on equity of -79.1%.
What is driving the score
- RSI Neutral: +5
- Strong Downtrend: -12
- MACD Bearish: -8
- Weak Profit Margin (0.0%): -8
- Strong Liquidity (11.38 Current Ratio): +8
- Negative ROE (-79.1%): -10
- High P/B (15.46): -5
- Strong Long-term Uptrend: +8
- Extreme Overextension (+293.4% over 1 year): -15
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full RVMD report
Revolution Medicines, Inc. (RVMD) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze RVMD Now →📰 Latest Update
First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
Wed, October 7, 2026 at 4:27 AM UTC 3 min read
Revolution Medicines (RVMD) has launched a first-line clinical trial targeting RAS G12D pancreatic cancer, a significant step that could potentially transform treatment options for this challenging disease. This trial is crucial for investors as it positions RVMD at the forefront of innovative cancer therapies, potentially leading to increased market interest and revenue opportunities. Positive outcomes could enhance the company's valuation and attract further investment in its pipeline.